Clinical Trials Browser

Completed × INDUSTRY × NET × Clear all

Somatostatin Receptor-positive Neuroendocrine Tumor

NCT03910660 2025-10-20

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Phase 1/2 Completed

98 enrolled

EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT06358001 2025-09-22

EchoTip AcuCore Post-Market Clinical Study

Completed

183 enrolled

EndocrineGastrointestinalLymphoidNET

Autoimmune Pancreatitis, Adenocarcinoma, Carcinoma, Hepatocellular, Lymphoma, Neoplasm Metastasis, Cholangiocarcinoma, Neuroendocrine Tumors, Pancreatitis, Chronic

NCT05077384 2025-09-16

Open-label Study of Surufatinib in Japanese Patients

Phase 1/2 Completed

36 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05017662 2025-09-04

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Phase NA Completed

20 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Phase 1/2 Completed

316 enrolled

CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT02279433 2025-06-24

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

Phase 1 Completed

46 enrolled

EndocrineGastrointestinalNETThoracic

Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT03037385 2025-05-31

ARROW

Phase 1/2 Completed

590 enrolled 58 charts 5 FDA

EndocrineGastrointestinalHead & NeckNETThoracic

Thyroid Cancer, Papillary, Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Carcinoma, Medullary, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 2a

Clinical Trials

LUTATHERA Injection General Use Result Survey

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

EchoTip AcuCore Post-Market Clinical Study

Open-label Study of Surufatinib in Japanese Patients

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

ARROW

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

BackSOM

PREF-NET

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RELAX

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

ELECT

NET729

DUET-1

NETTER-1

EXPLAIN

RADIANT-4

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

SYMNET

ATLANT

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

OPERA

Community-based Neuroendocrine Tumor (NET) Research Study

An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

SONNET

RAMSETE/CDE16

SOPRANo

Non Interventional Post Marketing Programme in Neuroendocrine Tumours

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

RECOSY

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors